Welcome to the e-CCO Library!

P063: Faecal calprotectin as a non-invasive treatment target to predict mucosal healing and histological remission in asymptomatic ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Correia Varela Almeida1*, J.M. Vázquez Morón1, E. Gómez Delgado1, H. Pallarés Manrique1, A. Talavera Fabuel2, A. Bejarano García1

Created: Thursday, 21 February 2019, 9:14 AM
P063: HDAC as versatile regulators of the intestinal epithelial barrier in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Friedrich M., Ganther J., Breiderhoff T., Rosenthal R., Glauben R., Siegmund B.

Created: Wednesday, 20 February 2019, 10:36 AM
P063: Host-mycobiome interactions during the resolution of inflammation in experimental colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: De Salvo, C.(1)*;Wargo, H.(1);Vidmar, K.(1);Di Martino, L.(2);Mahabaleshwar, G.(1);Cominelli, F.(2);Ghannoum, M.(2);Pizarro, T.(1);
Created: Friday, 14 July 2023, 10:48 AM
P063: Representative and comprehensive analysis of colonic and ileac biopsies from IBD patients by gene expression profiling using the straightforward, fast, and affordable novel application Whole Transcriptome AmpliSeq on the Ion Torrent NGS platform
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

F. Raulf*1, L. Roth1, C. Delucis-Bronn1, A. Begrich1, G. Wieczorek1, D. Picard2, J. Rush1, C. Beglinger3, P. Hruz4

Created: Friday, 22 February 2019, 9:41 AM
P063: The immunological landscape of intestinal fibrosis in Crohn’s Disease.
Year: 2021
Source: ECCO'21 Virtual
Authors: Jacobs, I.(1,2);Creyns, B.(1,2);Dragoni, G.(2,3);Cremer, J.(1,2);Bislenghi, G.(4);D'Hoore, A.(4);Ke, B.J.(2);Matteoli, G.(2);De Hertogh, G.(5);Ferrante, M.(2,4);Joao, G.S.(2,4);Breynaert, C.(1,6);Vermeire, S.(2,4);Verstockt, B.(2,4);Vanuytsel, T.(2,4);
Created: Wednesday, 2 June 2021, 4:12 PM
P064 Exosomes from mesenchymal stromal cells reduce murine colonic inflammation via a macrophage-dependent mechanism
Year: 2020
Source:

ECCO'20 Vienna

Authors:

X.R. Wu1, P. Lan1, X.J. Wu1, X. Gao2

Created: Thursday, 30 January 2020, 10:12 AM
P0640: Development and characterization of LQ080x7x7x7 a novel extended half-life bispecific TL1A/IL-23 p19 single domain antibody for the treatment of IBD
Year: 2025
Source: ECCO'25
Authors: Wanx7x7x7 Y.(1)*;Zhux7x7x7 M.(1);Gaix7x7x7 J.(1);Huangx7x7x7 Y.(1);Hux7x7x7 Y.(1);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0641: Efficacy of Vedolizumab and Ustekinumab Following Cyclosporine Induction in Acute Severe Ulcerative Colitis: A Retrospective Cohort Study.
Year: 2025
Source: ECCO'25
Authors: Harbx7x7x7 M.(1)*;Bazinx7x7x7 T.(1);Solenex7x7x7 D.(1);Bresteaux7x7x7 C.(1);El Khatibx7x7x7 M.(1);Bourdillelx7x7x7 J.(1);Colasx7x7x7 C.(1);Corcosx7x7x7 O.(1);Billiauwsx7x7x7 L.(1);Jolyx7x7x7 F.(1);Nuzzox7x7x7 A.(1);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0642: Assessment of the real-world effectiveness of upadacitinib in patients with moderate-severe ulcerative colitis in a global real-world setting
Year: 2025
Source: ECCO'25
Authors: Seidelinx7x7x7 J.B.(1)*;Marin-Jimenezx7x7x7 I.(2);Dawodx7x7x7 F.(3);Lukanovax7x7x7 R.(3);Jonesx7x7x7 W.(3);Morrisetx7x7x7 P.(4);Sharmax7x7x7 D.(4);Siegelx7x7x7 C.(5);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0643: Development of a personalized infliximab dosing algorithm for Acute Severe Ulcerative Colitis: results of a multi-center pharmacometrics analysis
Year: 2025
Source: ECCO'25
Authors: Niyigena x7x7x7 E.(1);Hoffertx7x7x7 Y.(1);Peyrin-Biroulet x7x7x7 L.(2);Afif x7x7x7 W.(3);Roblin x7x7x7 X.(4);Hanžel x7x7x7 J.(5);Papamichael x7x7x7 K.(6);Kobayashi x7x7x7 T.(7);Wang x7x7x7 Z.(1);Verstockt x7x7x7 B.(8);Vermeire x7x7x7 S.(8);Vande Casteele x7x7x7 N.(9);Battat x7x7x7 R.(10);Dreesenx7x7x7 E.(1)*;
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0645: CDAI underestimates disease activity in overweight patients with Crohn’s Disease when compared to endoscopic assessment
Year: 2025
Source: ECCO'25
Authors: Campbellx7x7x7 I.(1)*;Brownsonx7x7x7 E.(2);Wirzx7x7x7 A.(3);Seenanx7x7x7 J.P.(1);MacDonaldx7x7x7 J.(1);Gerasimidisx7x7x7 K.(4);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0646: Significant mental health and fatigue burden found in tertiary paediatric IBD service in Australia
Year: 2025
Source: ECCO'25
Authors: Au Yeungx7x7x7 S.T.(1x7x7x72);Youx7x7x7 D.(2x7x7x73);Mahmoodx7x7x7 D.(2);Tanox7x7x7 M.(1);Chidgeyx7x7x7 T.(1);Magoffinx7x7x7 A.(1);O’Loughlinx7x7x7 E.(1);Thacker x7x7x7 K.(1);Duttx7x7x7 S.(1x7x7x73)*;
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0647: Impact of Age and Comorbidities on Treatment Outcomes and Mortality in Patients Admitted for Ulcerative Colitis Flares: A 20-Year Retrospective Cohort Study
Year: 2025
Source: ECCO'25
Authors: Tejero Juradox7x7x7 R.(1)*;el Fallous el Mraghidx7x7x7 M.(1);Carrillo Cuberox7x7x7 B.(1);Alañón Martínezx7x7x7 P.(1);Marín Pedrosax7x7x7 S.(1);Soto Escribanox7x7x7 P.(1);Benítez Canterox7x7x7 J.M.(1);Iglesias Floresx7x7x7 E.M.(1);Gros Alcaldex7x7x7 B.(1);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0648: The Safety and Effects of a Dual-Strain Probiotic Versus Placebo on Fatigue in Patients with Ulcerative Colitis
Year: 2025
Source: ECCO'25
Authors: Carrollx7x7x7 A.(1)*;Walkerx7x7x7 C.(1);Magdeldinx7x7x7 H.(1);Breslinx7x7x7 N.(1);O'Donnellx7x7x7 S.(1);Ryanx7x7x7 B.(1);McNamarax7x7x7 D.(1);Corrx7x7x7 S.(2);O'Connorx7x7x7 A.(1);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0649: Acceptability and Tolerance of Risankizumab Treatment Administered via On-Body Injector in Patients with Crohn’s Disease: Results of the Nationwide ACCEPT-OBI Study
Year: 2025
Source: ECCO'25
Authors: Buissonx7x7x7 A.(1)*;Gebarax7x7x7 K.(2);Peyrin-Birouletx7x7x7 L.(3);Boschettix7x7x7 G.(4);Gilletta de Saint Josephx7x7x7 C.(5);Brixix7x7x7 H.(6);Juilleratx7x7x7 P.(7);Serrerox7x7x7 M.(8);Vuittonx7x7x7 L.(9);Hébuternex7x7x7 X.(10);Caillox7x7x7 L.(11);Blainx7x7x7 A.(12);Lahariex7x7x7 D.(13);Pereirax7x7x7 B.(1);Fumeryx7x7x7 M.(14);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P064: 3-oxo-C12:2, a Quorum Sensing molecule from the gut, exerts anti-inflammatory effects through a bitter taste receptor
Year: 2021
Source: ECCO'21 Virtual
Authors: Coquant, G.(1);Aguanno, D.(2);Peyrottes, A.(3);Brot, L.(1);Belloir, C.(4);Briand, L.(4);Grill, J.P.(1);Thenet, S.(2);De Sordi, L.(1);Seksik, P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P064: EBI2 and oxysterols in the development of intestinal lymphoid structures and colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Wyss A.*1, Raselli T.1, Schmelczer G.1, Spalinger M.1, Atrott K.1, Frey-Wagner I.1, Sailer A.W.2, Rogler G.1, Misselwitz B.1

Created: Wednesday, 20 February 2019, 10:36 AM
P064: High intestinal Secretory Leukocyte Protease Inhibitor (SLPI) expression correlates with abundant neutrophilic inflammation and identifies Inflammatory Bowel Disease patients with a strong IL-17 response.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Nugteren, S.(1);Calado, B.(1)*;Simons-Oosterhuis, Y.(1);H. Hulleman-van Haaften, D.(1);Klomberg, R.(2);Tuk, B.(1);Charrout, M.(3);J. Lindenbergh-Kortleve, D.(1);K. Smits, W.(1);Doukas, M.(4);A. Sanders, M.(5);van Beek, G.(5);C. Escher, J.(2);de Ridder, L.(2);N. Samsom, J.(1);
Created: Friday, 14 July 2023, 10:48 AM
P064: IMU-838, a Small Molecule DHODH Inhibitor in Phase 2 Clinical Trial for Ulcerative Colitis, Shows Potent Anti-inflammatory Activity in Cell-Culture-Based and In Vivo Systems
Year: 2022
Source: ECCO'22
Authors: Peelen , E.(1);Muehler , A.(1);Vitt , D.(1);Kohlhof , H.(1);
Created: Friday, 11 February 2022, 3:52 PM
P064: Intestinal expression of LAG-3 correlates with inflammatory activity and response to biological therapy in ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Slevin1*, M. Tan1, C. Lahiff1, K. Williamson1, A. Geremia1, S. Hughes2, K. Leavens2, K. Nevin2, D.J.B. Marks2, R. Tarzi2, N. Srinivasan2, C. Arancibia1, S. Keshav1

Created: Thursday, 21 February 2019, 9:14 AM